SCHEMBL26554377

SCHEMBL26554377

CC[C@H]1O[C@@H](n2ccc(=O)cc2)[C@H](O)[C@@H]1C

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 1/20 0.33
SLC28A2 O43868 1/20 0.33
SLC29A1 Q99808 1/20 0.33
SLC28A3 Q9HAS3 1/20 0.33
SLC5A2 P31639 2/20 0.32
LMNA P02545 1/20 0.32
THRB P10828 1/20 0.32
MTOR P42345 1/20 0.32
MDM2 Q00987 1/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
MAPT P10636 1/20 0.31
CDA P32320 1/20 0.31
ADK P55263 1/20 0.31
P2RY6 Q15077 2/20 0.30
P2RY2 P41231 2/20 0.30
P2RY14 Q15391 1/20 0.30
P2RY4 P51582 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26554402 1.00 SLC28A1 (0.33) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL26554401 0.82
SCHEMBL26554395 0.81 CDA (0.39) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL26554372 0.78 LMNA (0.36) LMNATHRBMAPT
SCHEMBL7023707 0.76 SLC28A1 (0.55) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL7023712 0.76 SLC28A1 (0.55) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL26554459 0.75 MAPT (0.40) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL26554457 0.75 MAPT (0.40) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL26554384 0.74 MEN1 (0.41) LMNA
SCHEMBL12222459 0.73 SLC28A1 (0.66) SLC28A1SLC28A2SLC29A1SLC28A3P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-11-16 US disclosed
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF SLC28A1 204/4885SLC28A2 183/4885SLC29A1 666/4885
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF SLC28A1 204/4885SLC28A2 183/4885SLC29A1 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.